Burney Co. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Burney Co. bought a new stake of 3,487 shares in Regeneron (NASDAQ:REGN) in Q4, valued at approximately $2.69 million.
• Insiders have been selling: 3,774 shares worth about $2.94 million were sold in the last 90 days — including Director Huda Y. Zoghbi (1,638 shares at $781.33) and SVP Jason Pitofsky (2,036 shares at $778.52) — while insiders still own 7.02% and institutions own 83.31% of the stock.
• Fundamentals and payout: Regeneron beat Q4 estimates with $11.44 EPS and $3.88B revenue, raised its quarterly dividend to $0.94 (annualized $3.76, 0.5% yield), and carries a consensus analyst stance of a "Moderate Buy" with an average target near $811.96.

Burney Co. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,487 shares of the biopharmaceutical company's stock, valued at approximately $2,692,000.

A number of other large investors have also made changes to their positions in REGN. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $31,000. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. Caitlin John LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $34,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $38,000. Institutional investors own 83.31% of the company's stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the firm's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the firm's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company's stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,774 shares of company stock worth $2,942,738. Insiders own 7.02% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Barclays assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, March 6th. They issued an "overweight" rating and a $923.00 price objective for the company. Evercore upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an "outperform" rating in a research report on Thursday, January 22nd. Finally, Sanford C. Bernstein lowered their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating for the company in a report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $811.96.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $748.87 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a market cap of $79.17 billion, a price-to-earnings ratio of 18.02, a P/E/G ratio of 1.99 and a beta of 0.40. The firm has a 50-day moving average of $767.42 and a 200-day moving average of $721.06. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the business posted $12.07 EPS. Regeneron Pharmaceuticals's revenue was up 2.5% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.